Trial Profile
Sifrol (pramipexole) impact on RLS related quality of life: a 12-weeks observational non-interventional study in patients with primary RLS.
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 08 Nov 2013
Price :
$35
*
At a glance
- Drugs Pramipexole (Primary)
- Indications Restless legs syndrome
- Focus Therapeutic Use
- Sponsors Boehringer Ingelheim Pharmaceuticals
- 08 Jul 2009 Actual patient number (2093) added as reported by ClinicalTrials.gov.
- 10 Feb 2009 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 16 Oct 2007 New trial record.